Vandana Singh
·
August 12, 2025
Benzinga
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
read more
September 9, 2025
September 5, 2025
July 17, 2025
Financial Times
August 20, 2025
August 11, 2025
Bloomberg